Russian diplomat calls talks with Syrian opposition 'constructive'Russian Politics & Diplomacy March 01, 21:52
WADA welcomes Putin’s statement urging Russia to heed demands of McLaren reportSport March 01, 21:27
Moldova’s president initiates process of national reconciliation over TransnistriaWorld March 01, 21:14
Russian Foreign Ministry: Any sanctions against Syria to weaken anti-terrorist frontRussian Politics & Diplomacy March 01, 21:05
Russia rejects Al Jazeera’s report on alleged cooperation with terrorists in AfghanistanRussian Politics & Diplomacy March 01, 20:04
Moldova’s government recalls ambassador to RussiaWorld March 01, 20:02
OSCE envoy says Contact Group discussed recognition of DPR, LPR documents by MoscowWorld March 01, 20:00
Russian senator believes European Parliament’s resolutions on Syria not to solve crisisRussian Politics & Diplomacy March 01, 18:56
Dire Straits Experience to kick off their 2017 world tour in RussiaSociety & Culture March 01, 18:48
ST. PETERSBURG, December 29. /TASS/. A group of scientists at the St. Petersburg-based Research Institute of Influenza have developed a vaccine against the deadly Ebola virus and its trials are due to complete in Africa in February, the director of the institute said on Monday.
“The candidate vaccine against Ebola created by a group of young scientists of our institute is undergoing tests for genetic stability,” Oleg Kiselev said, adding that the vaccine will be called “candidate” until its industrial production begins.
The vaccine has been already sent to the Virology Center of the Ministry of Defense and will be first tested on animals. The clinical tests involving volunteers will be conducted in Africa.
All the stages of trials are due to wrap up in February, Kiselev said.
The latest figures by the World Health Organization (WHO) show that the death toll from the current Ebola outbreak has reached 7,693 and as many as 19,695 have been infected. Most deaths were reported in the hardest-hit West African countries — Liberia, Sierra Leone and Guinea.